Literature DB >> 10219775

The neuropathology of schizophrenia. A critical review of the data and their interpretation.

P J Harrison1.   

Abstract

Despite a hundred years' research, the neuropathology of schizophrenia remains obscure. However, neither can the null hypothesis be sustained--that it is a 'functional' psychosis, a disorder with no structural basis. A number of abnormalities have been identified and confirmed by meta-analysis, including ventricular enlargement and decreased cerebral (cortical and hippocampal) volume. These are characteristic of schizophrenia as a whole, rather than being restricted to a subtype, and are present in first-episode, unmedicated patients. There is considerable evidence for preferential involvement of the temporal lobe and moderate evidence for an alteration in normal cerebral asymmetries. There are several candidates for the histological and molecular correlates of the macroscopic features. The probable proximal explanation for decreased cortical volume is reduced neuropil and neuronal size, rather than a loss of neurons. These morphometric changes are in turn suggestive of alterations in synaptic, dendritic and axonal organization, a view supported by immunocytochemical and ultrastructural findings. Pathology in subcortical structures is not well established, apart from dorsal thalamic nuclei, which are smaller and contain fewer neurons. Other cytoarchitectural features of schizophrenia which are often discussed, notably entorhinal cortex heterotopias and hippocampal neuronal disarray, remain to be confirmed. The phenotype of the affected neuronal and synaptic populations is uncertain. A case can be made for impairment of hippocampal and corticocortical excitatory pathways, but in general the relationship between neurochemical findings (which centre upon dopamine, 5-hydroxytryptamine, glutamate and GABA systems) and the neuropathology of schizophrenia is unclear. Gliosis is not an intrinsic feature; its absence supports, but does not prove, the prevailing hypothesis that schizophrenia is a disorder of prenatal neurodevelopment. The cognitive impairment which frequently accompanies schizophrenia is not due to Alzheimer's disease or any other recognized neurodegenerative disorder. Its basis is unknown. Functional imaging data indicate that the pathophysiology of schizophrenia reflects aberrant activity in, and integration of, the components of distributed circuits involving the prefrontal cortex, hippocampus and certain subcortical structures. It is hypothesized that the neuropathological features represent the anatomical substrate of these functional abnormalities in neural connectivity. Investigation of this proposal is a goal of current neuropathological studies, which must also seek (i) to establish which of the recent histological findings are robust and cardinal, and (ii) to define the relationship of the pathological phenotype with the clinical syndrome, its neurochemistry and its pathogenesis.

Entities:  

Mesh:

Year:  1999        PMID: 10219775     DOI: 10.1093/brain/122.4.593

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  355 in total

1.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics.

Authors:  G J Popken; W E Bunney; S G Potkin; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 3.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

4.  Cerebellar projections to the prefrontal cortex of the primate.

Authors:  F A Middleton; P L Strick
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

5.  Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.

Authors:  E A Thomas; B Dean; G Pavey; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

6.  MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms.

Authors:  Beng-Choon Ho
Journal:  Schizophr Res       Date:  2007-08-29       Impact factor: 4.939

7.  A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

Authors:  Holly Moore; J David Jentsch; Mehdi Ghajarnia; Mark A Geyer; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2006-04-11       Impact factor: 13.382

Review 8.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 9.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

10.  NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

Authors:  Lucila Kargieman; Noemí Santana; Guadalupe Mengod; Pau Celada; Francesc Artigas
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.